Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selumetinib and MK-2206 in Refractory Advanced Biliary Cancers
NCT01859182Phase 2Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Jan 2013
- Primary completion
- May 2013
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of selumetinib, MK-2206 in biliary tract cancer (BTC), gallbladder cancer, cholangiocarcinoma (CCA), sponsored by National Cancer Institute. Planned start Jan 2013; status: withdrawn.
02
Drugs
selumetinibMK-2206
03
Conditions
biliary tract cancer (BTC)gallbladder cancercholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT01859182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01859182.